<MedlineCitation Status="Completed">
<MedlineID>10011149</MedlineID>
<PMID>84676</PMID>
<DateCreated>
<Year>1979</Year>
<Month>04</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>04</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised>
<Year>2001</Year>
<Month>11</Month>
<Day>02</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0004-3591</ISSN>
<JournalIssue>
<Volume>22</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1979</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Detection of intermediate complexes by evaluation of the difference between gamma-globulin and IgG concentrations.</ArticleTitle>
<Pagination>
<MedlinePgn>141-4</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>A simple analysis based on techniques readily available in the routine clinical laboratory has been presented for identification of patients with moderate and high levels of intermediate complexes. If the gamma-globulin concentration determined by serum protein electrophoresis minus the IgG concentration determined by radial immunodiffusion exceeds 1.0 gm/dl, intermediate complexes of IgG should be present in concentrations greater than 0.5 gm/dl. In principle, any disease association with sufficient polymerization of IgG might cause an abnormal result with this analysis. Furthermore, sera from patients with liver disease and marked beta-gamma-bridging on electrophoresis may also give abnormal values.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Nardella</LastName>
<ForeName>F A</ForeName>
<Initials>FA</Initials>
</Author>
<Author>
<LastName>Gilliland</LastName>
<ForeName>B C</ForeName>
<Initials>BC</Initials>
</Author>
<Author>
<LastName>Mannik</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Arthritis Rheum</MedlineTA>
<NlmUniqueID>0370605</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Gamma-Globulins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9009-79-4</RegistryNumber>
<NameOfSubstance>Rheumatoid Factor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Arthritis, Rheumatoid</DescriptorName>
<QualifierName>blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Blood Donors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Blood Protein Electrophoresis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Electrophoresis, Cellulose Acetate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Evaluation Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Gamma-Globulins</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Immunoglobulin G</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Methods</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Purpura</DescriptorName>
<QualifierName>blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Rheumatoid Factor</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Support, U.S. Gov't, P.H.S.</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
